{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lymphocyte+gene+therapy&page=4", "query": { "intervention": "lymphocyte gene therapy", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 92, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lymphocyte+gene+therapy&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lymphocyte+gene+therapy&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T02:42:46.939Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00028236", "title": "Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "Gene-Transduced Autologous CD34+ Stem Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "20 Years", "sex": "ALL", "summary": "18 Months to 20 Years" }, "enrollment_count": 3, "start_date": "2001-12-10", "completion_date": "2011-07-25", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028236" }, { "nct_id": "NCT05660369", "title": "CARv3-TEAM-E T Cells in Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent Glioma" ], "interventions": [ { "name": "CARv3-TEAM-E T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marcela V. Maus, M.D.,Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-03-22", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660369" }, { "nct_id": "NCT06295159", "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Advanced Melanoma", "Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-05-17", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06295159" }, { "nct_id": "NCT01586403", "title": "Transfer of Genetically Engineered Lymphocytes in Melanoma Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dose 1", "type": "BIOLOGICAL" }, { "name": "Dose 2", "type": "BIOLOGICAL" }, { "name": "Dose 3", "type": "BIOLOGICAL" }, { "name": "Dose 4", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2012-07", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586403" }, { "nct_id": "NCT02062359", "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Metastatic Melanoma" ], "interventions": [ { "name": "Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 2, "start_date": "2014-02", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2016-06-24", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02062359" }, { "nct_id": "NCT00866879", "title": "Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant Rejection" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Demographic Data, Medical History, and Donor Data", "type": "OTHER" }, { "name": "Blood Draws for Control Group", "type": "PROCEDURE" }, { "name": "Blood Draws for Experimental Group", "type": "PROCEDURE" }, { "name": "Donor Blood Draws", "type": "PROCEDURE" }, { "name": "Donor Information", "type": "OTHER" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 275, "start_date": "2007-06", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2019-06-28", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866879" }, { "nct_id": "NCT01457131", "title": "Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Metastatic Melanoma", "Metastatic Renal Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-12 & Anti-NY ESO1 TCR PBL", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2, "start_date": "2011-10-06", "completion_date": "2013-08-07", "has_results": false, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457131" }, { "nct_id": "NCT04426669", "title": "A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Epithelial Cancer", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Cancer, Gastrointestinal", "Gastrointestinal Cancer", "Colo-rectal Cancer", "Pancreatic Cancer", "Gall Bladder Cancer", "Colon Cancer", "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tumor-Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2020-05-15", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426669" }, { "nct_id": "NCT00058773", "title": "Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease", "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Infusion of EBV Specific Cytotoxic T-Lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "1996-01", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2012-11-06", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058773" }, { "nct_id": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Mesothelioma", "Lung Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2012-05-04", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-10-10T02:42:46.939Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01583686" } ] }